Inebilizumab

Last Updated: 09/19/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 197 publications

IgG4-related disease - treatment with anti-CD20, anti-CD19 antibodies, and other new drugs.

IgG4-related disease - treatment with anti-CD20, anti-CD19 antibodies, and other new drugs.

Journal: Klinicka onkologie : casopis Ceske a Slovenske onkologicke spolecnosti

Published: August 28, 2026

Management of Exacerbations and Rescue Therapy: A Prespecified Analysis of the Phase 3 Myasthenia Gravis Inebilizumab Randomized Clinical Trial.

Management of Exacerbations and Rescue Therapy: A Prespecified Analysis of the Phase 3 Myasthenia Gravis Inebilizumab Randomized Clinical Trial.

Journal: JAMA neurology

Published: August 10, 2026

Clinical efficacy and cost per improved outcome of treatments for generalized myasthenia gravis: evidence from a network meta-analysis and cost-per-responder analysis.

Clinical efficacy and cost per improved outcome of treatments for generalized myasthenia gravis: evidence from a network meta-analysis and cost-per-responder analysis.

Journal: Current medical research and opinion

Published: July 24, 2026

Interstitial lung disease and primary Sjögren's syndrome combined with anti-AQP4 antibody-positive neuromyelitis optica spectrum disorder: a case report

Interstitial lung disease and primary Sjögren's syndrome combined with anti-AQP4 antibody-positive neuromyelitis optica spectrum disorder: a case report

Journal: Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases

Published: June 29, 2026

Inebilizumab (Uplizna) for myasthenia gravis.

Inebilizumab (Uplizna) for myasthenia gravis.

Journal: The Medical letter on drugs and therapeutics

Published: June 25, 2026

Neuroimmunological overlap syndromes in optic neuritis, myelitis, and connective tissue diseases.

Neuroimmunological overlap syndromes in optic neuritis, myelitis, and connective tissue diseases.

Journal: Frontiers in neurology

Published: May 21, 2026

Inebilizumab in AQP4-Seropositive NMOSD: One-Year Follow-Up From a Multicenter, Real-World Study.

Inebilizumab in AQP4-Seropositive NMOSD: One-Year Follow-Up From a Multicenter, Real-World Study.

Journal: Annals of clinical and translational neurology

Published: May 12, 2026

Real-World Multicenter Cohort Study of Inebilizumab vs Low-Dose Rituximab in Neuromyelitis Optica Spectrum Disorders.

Real-World Multicenter Cohort Study of Inebilizumab vs Low-Dose Rituximab in Neuromyelitis Optica Spectrum Disorders.

Journal: Neurology(R) neuroimmunology & neuroinflammation

Published: April 27, 2026

From inflammatory initiation to fibrotic remodeling: mechanisms and precision therapeutic strategies in otorhinolaryngologic involvement of IgG4-related disease.

From inflammatory initiation to fibrotic remodeling: mechanisms and precision therapeutic strategies in otorhinolaryngologic involvement of IgG4-related disease.

Journal: Frontiers in medicine

Published: April 19, 2026

Effectiveness and Safety of Inebilizumab for IgG4-Related Disease in a Real-World Clinical Setting in Japan: Protocol for a Long-Term Prospective Observational Study (4SigHT Study).

Effectiveness and Safety of Inebilizumab for IgG4-Related Disease in a Real-World Clinical Setting in Japan: Protocol for a Long-Term Prospective Observational Study (4SigHT Study).

Journal: Rheumatology and therapy

Published: March 31, 2026

Safety and Effectiveness of Inebilizumab in Patients with Neuromyelitis Optica Spectrum Disorder: Interim Analysis of a Post-marketing Surveillance in Japan.

Safety and Effectiveness of Inebilizumab in Patients with Neuromyelitis Optica Spectrum Disorder: Interim Analysis of a Post-marketing Surveillance in Japan.

Journal: Neurology and therapy

Published: March 27, 2026

Patient-reported outcomes in Chinese patients with AQP4-IgG-positive neuromyelitis optica spectrum disorder on inebilizumab therapy: a cross-sectional study.

Patient-reported outcomes in Chinese patients with AQP4-IgG-positive neuromyelitis optica spectrum disorder on inebilizumab therapy: a cross-sectional study.

Journal: BMC neurology

Published: March 24, 2026

Showing 1-12 of 197

Last Updated: 09/19/2026